Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Investigation of the Prognostic Significance of Vasculogenic Mimicry and Its Inhibition by Sorafenib in Canine Mammary Gland Tumors

Full text
Author(s):
Prado, Maria Carolina Mangini [1] ; Macedo, Sofia de Almeida Losant [1] ; Guiraldelli, Giulia Gumiero [2] ; de Faria Lainetti, Patricia [1] ; Leis-Filho, Antonio Fernando [1] ; Kobayashi, Priscila Emiko [2] ; Laufer-Amorim, Renee [2] ; Fonseca-Alves, Carlos Eduardo [1, 3]
Total Authors: 8
Affiliation:
[1] Sao Paulo State Univ UNESP, Dept Vet Surg & Anesthesiol, Botucatu, SP - Brazil
[2] Sao Paulo State Univ UNESP, Dept Vet Clin, Botucatu, SP - Brazil
[3] Univ Paulista UNIP, Inst Hlth Sci, Bauru, SP - Brazil
Total Affiliations: 3
Document type: Journal article
Source: FRONTIERS IN ONCOLOGY; v. 9, DEC 19 2019.
Web of Science Citations: 0
Abstract

Canine mammary gland tumor (CMT) is one of the most important tumors in intact female dogs, and due its similarity to human breast cancer (BC), it is considered a model in comparative oncology. A subset of mammary gland tumors can show aggressive behavior, and a recurrent histological finding is the presence of vasculogenic mimicry (VM). VM is a process in which highly aggressive cancer cells fuse, forming fluid-conducting channels without endothelial cells. Although, VM has been described in canine inflammatory carcinoma, no previous studies have investigated the prognostic and predictive significance of VM in CMT. Thus, this research aimed to investigate the prognostic significance of VM in vivo and the capacity of sorafenib to inhibit VM in vitro. VM was identified in situ in formalin-fixed paraffin-embedded CMT samples (n = 248) using CD31/PAS double staining. VM was identified in 33% of tumors (82/248). The presence of VM was more strongly related to tumor grade than to histological subtype. Patients with positive VM experienced shorter survival times than dogs without VM (P < 0.0001). Due to the importance of the VEGF-A/VEGFR-2 autocrine feed-forward loop in epithelial tumors, we investigated the association between VEGF-A and VEGFR-2 expression by neoplastic tumor cells and the associations of VEGF-A or VEGFR-2 expression with VM. Among the VM-positive samples, all (n = 82) showed high scores (3 or 4) for VEGF-A and VEGFR-2, indicating that VM was a common finding in tumors overexpressing VEGF-A and VEGFR-2. Thus, we cultured two CMT primary cell lines with VM abilities (CM9 and CM60) in vitro and evaluated the anti-tumoral effect of sorafenib. The CM9 cell line showed a half maximal inhibitory concentration (IC50) of 2.61 mu M, and the CM60 cell line showed an IC50 of 1.34 mu M. We performed a VM assay in vitro and treated each cell line with an IC50 dose of sorafenib, which was able to inhibit VM in vitro. Overall, our results indicated that VM was a prognostic factor for dogs bearing CMT and that sorafenib had an inhibitory effect on VM in CMT cancer cells in vitro. (AU)

FAPESP's process: 18/17109-9 - In vitro evaluation of Sorafenib and Rapamycin antitumor activity in canine mammary carcinoma metastatic cells
Grantee:Giulia Gumiero Guiraldelli
Support type: Scholarships in Brazil - Scientific Initiation
FAPESP's process: 15/25400-7 - In vitro and molecular characterization of canine prostatic cells and evaluation of antitumor response against target drugs
Grantee:Carlos Eduardo Fonseca Alves
Support type: Scholarships in Brazil - Post-Doctorate